Posted on September 10, 20259/10/25
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
Posted on September 10, 20259/10/25
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
Posted on August 25, 20258/25/25
Evaluation of HTA Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access
Posted on July 21, 20257/21/25
Empowering Scientific Dialogue: Key Takeaways from the FDA’s SIUU Guidance
Posted on July 3, 20257/3/25
Staying Ahead of the Curve in Pharmacovigilance: Inspection Metrics Report for 2023 by Egyptian Drug Authority (EDA)
Posted on July 1, 20257/1/25
Staying Ahead of the Curve in Pharmacovigilance: ANVISA RDC No. 967/25
Posted on May 29, 20255/29/25